Cardiff Oncology Inc (CRDF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardiff Oncology Inc (CRDF) has a cash flow conversion efficiency ratio of -0.131x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.97 Million) by net assets ($45.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cardiff Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Cardiff Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cardiff Oncology Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Cardiff Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiff Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
John Hancock Investors Closed Fund
NYSE:JHI
|
0.004x |
|
Menang Corporation (Malaysia) Bhd
KLSE:1694
|
0.058x |
|
Gold Resource Corporation
NYSE MKT:GORO
|
-0.013x |
|
Intelligent Digital Integrated Security Co. Ltd
KQ:143160
|
0.041x |
|
Aurora World Corporation
KQ:039830
|
0.003x |
|
Hanshin Const
KO:004960
|
-0.050x |
|
Willbes
KO:008600
|
0.151x |
|
Thien Viet Securities JSC
VN:TVS
|
0.196x |
Annual Cash Flow Conversion Efficiency for Cardiff Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Cardiff Oncology Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see CRDF company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $45.39 Million | $-37.92 Million | -0.836x | -83.87% |
| 2024-12-31 | $82.95 Million | $-37.69 Million | -0.454x | -2.60% |
| 2023-12-31 | $69.74 Million | $-30.89 Million | -0.443x | -39.26% |
| 2022-12-31 | $106.34 Million | $-33.82 Million | -0.318x | -93.82% |
| 2021-12-31 | $140.42 Million | $-23.04 Million | -0.164x | -28.89% |
| 2020-12-31 | $128.16 Million | $-16.31 Million | -0.127x | +92.98% |
| 2019-12-31 | $7.31 Million | $-13.27 Million | -1.815x | -38.63% |
| 2018-12-31 | $10.08 Million | $-13.20 Million | -1.309x | +63.42% |
| 2017-12-31 | $6.51 Million | $-23.28 Million | -3.578x | -127.89% |
| 2016-12-31 | $19.77 Million | $-31.04 Million | -1.570x | -245.73% |
| 2015-12-31 | $48.70 Million | $-22.12 Million | -0.454x | +70.21% |
| 2014-12-31 | $8.35 Million | $-12.73 Million | -1.524x | -324.83% |
| 2013-12-31 | $20.39 Million | $-7.32 Million | -0.359x | +84.23% |
| 2012-12-31 | $2.17 Million | $-4.93 Million | -2.275x | -598.70% |
| 2011-12-31 | $-4.23 Million | $-1.93 Million | 0.456x | +9.10% |
| 2010-12-31 | $-5.00 Million | $-2.09 Million | 0.418x | +28.84% |
| 2009-12-31 | $-3.79 Million | $-1.23 Million | 0.325x | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more